ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
41.60
0.20
( 0.48% )
Updated: 19:30:18
Realtime Data

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
41.60
Bid
41.00
Offer
41.60
Volume
3
41.00 Day's Range 41.60
0.00 52 Week Range 0.00
Market Cap
Previous Close
41.40
Open
41.00
Last Trade
1
@
41.6
Last Trade Time
19:30:18
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
19,785,726
Dividend Yield
-
PE Ratio
6.53
Earnings Per Share (EPS)
6.34
Revenue
684.6M
Net Profit
125.42M

About Biotest AG

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Dreieich, Deu
Founded
1946
Biotest AG is listed in the Pharmaceutical Preparations sector of the Tradegate (DE) with ticker BIO. The last closing price for Biotest was 41.40 €. Over the last year, Biotest shares have traded in a share price range of 0.00 € to 0.00 €.

Biotest currently has 19,785,726 shares in issue. The market capitalisation of Biotest is 819.13 € million. Biotest has a price to earnings ratio (PE ratio) of 6.53.

BIO Latest News

BioAlliance Pharma : Première réunion du Comité d’Experts international sur la mucite orale et la stratégie de dévelop...

Regulatory News : BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), Société d’innovation dédiée aux produits orphelins en cancérologie et aux produits de spécialité, annonce...

BioAlliance Pharma: Key milestones and consolidated accounts

First semester 2013 Grant of the Marketing Authorization for Sitavig® in the US Strong achievements in clinical trials with Livatag® (phase III) and Validive® (phase II...

BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at August 31, 2013

Regulatory News : BioAlliance Pharma (Paris:BIO) : Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général...

BioAlliance Pharma : Informations relatives au nombre total de droits de vote et d’actions composant le capital au 31 juill...

Regulatory News : BioAlliance Pharma (Paris:BIO) : Conformément à l’article L. 233-8 II du Code de commerce et à l’article 223-16 du Règlement général de l’Autorité des Marchés...

BioAlliance Pharma annonce le vif succès de son augmentation de capital

Montant brut levé : 8,7 millions d’euros ; Opération sursouscrite à hauteur de 155 % ; Exercice de la clause d’extension.

BioAlliance Pharma Expands and Strengthens Its Industrial Property Assets with Two Patent Grants

Regulatory News: BioAlliance Pharma SA (Paris:BIO), an innovative Company dedicated to the development of orphan oncology products and supportive care products, announces it was...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

BIO - Frequently Asked Questions (FAQ)

What is the current Biotest share price?
The current share price of Biotest is 41.60 €
How many Biotest shares are in issue?
Biotest has 19,785,726 shares in issue
What is the market cap of Biotest?
The market capitalisation of Biotest is EUR 819.13M
What is the 1 year trading range for Biotest share price?
Biotest has traded in the range of 0.00 € to 0.00 € during the past year
What is the PE ratio of Biotest?
The price to earnings ratio of Biotest is 6.53
What is the cash to sales ratio of Biotest?
The cash to sales ratio of Biotest is 1.2
What is the reporting currency for Biotest?
Biotest reports financial results in EUR
What is the latest annual turnover for Biotest?
The latest annual turnover of Biotest is EUR 684.6M
What is the latest annual profit for Biotest?
The latest annual profit of Biotest is EUR 125.42M
What is the registered address of Biotest?
The registered address for Biotest is LANDSTEINERSTRASSE 5, DREIEICH, 63303
What is the Biotest website address?
The website address for Biotest is www.biotest.de
Which industry sector does Biotest operate in?
Biotest operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
0RARAPT Therapeutics Inc
1.80 €
(125.00%)
18.04k
E3O1Nexoptic Technology Corp
0.026 €
(40.54%)
2.84k
4XHFreeport Resources Inc
0.021 €
(40.00%)
15.14k
FWR0Yumy Candy Company Inc the
0.035 €
(40.00%)
1.2M
28W0Aston Minerals Limited
0.0075 €
(36.36%)
83.28k
WWTWater Ways Technologies Inc
0.0045 €
(-95.91%)
2.53k
L7C2Windfall Geotek Inc
0.0025 €
(-70.59%)
40k
QP9Atco Mining Inc
0.003 €
(-55.88%)
1.5k
AWY0Percheron Therapeutics Ltd
0.002 €
(-55.56%)
155k
0PV2Moovly Media Inc
0.002 €
(-55.56%)
500
DI6Distribuidora Internacional De Alimentacion SA
0.0169 €
(1.20%)
1.81M
JSISamhallsbyggnadsbolaget Norden AB
0.383 €
(7.61%)
1.79M
D7GNel ASA
0.248 €
(-1.43%)
1.67M
FWR0Yumy Candy Company Inc the
0.035 €
(40.00%)
1.2M
PF8European Lithium Limited
0.0202 €
(-1.94%)
1.12M

Discussion

View Full Feed
Debunkinator Debunkinator 5 minutes ago
Very short week, let's make the most of it. 🎅🤶🦌🎄
ASII
Woodpecker3 Woodpecker3 5 minutes ago
$TSLA up 67% since Nov 5th election. Sales are slowing and stock price ripe for a tumble. https://www.marketwatch.com/story/there-are-signs-that-sales-of-tesla-cybertrucks-could-be-slowing-cbbc13d5?mod=mw_quote_news
TSLA
Uncle Monkey Uncle Monkey 5 minutes ago
terrible ceo must go!
CBRF
resx18 resx18 5 minutes ago
Good Morning $CBDW
CBDW
Zadie420 Zadie420 6 minutes ago
I don't know where this going. But, I am very surprised that the CEO has not said anything with their plan about going forward. How much they will charge for this treatment? are they applying for approval to the other jurisdictions?
In US alone we have potential of 40K patients form this tre
CKPT
resx18 resx18 6 minutes ago
Good Morning $KNOS
KNOS
blanka blanka 6 minutes ago
FCEL
Reefrad Reefrad 6 minutes ago
Except that longs have continued to average down at these manipulated prices (thanks to you and your filthy colleagues). So even with a 100-200 percent rise we will be fine.

Thanks for your concern!
NWBO
Investor2014 Investor2014 6 minutes ago
No halt. The news is out.

https://www.nasdaqtrader.com/Trader.aspx?id=TradeHalts
AVXL
Mufaso Mufaso 6 minutes ago
VKTX- There are a couple of things to note about #VK2735 having better efficacy/tolerability than #Tirzepatide (TZP). The first is you need less 1/3 to 1/2 the API to get the same weight loss. ( Let that sink in.) Viking (and their partner) will need to spend less capital and spend less for on g
API CDMO LLY
resx18 resx18 7 minutes ago
Good Morning $AURI
AURI
glenn1919 glenn1919 7 minutes ago
invz......laes......kulr.......frey..................https://stockcharts.com/h-sc/ui?s=laes&p=W&yr=1&mn=3&dy=0&id=p96837884856
Huggy Bear Huggy Bear 7 minutes ago
No can do. Deal with it.
HMBL
Huggy Bear Huggy Bear 9 minutes ago
If you want a boiler room site go join one. Plenty of them out there. All echo chamber rah rah rah, no dissent tolerated.

Ihub is not a boiler room, sorry to disappoint.
HMBL
WeTheMarket WeTheMarket 9 minutes ago
Blanka, I don't believe those are the final Treasury Department 45V guidelines we have been waiting for. Someone on another board pointed out that the information in your post was released a long time ago, and that the date is periodically updated. The final Treasury Department guidelines if/when th
FCEL
930 930 9 minutes ago
I placed an order today.
KULR
JSmith5 JSmith5 10 minutes ago
Then follow the law of the land and quit promoting warrants every 20 seconds

Isn't the whole history of this thing about not following the law? Is the Government suddenly going to get religion?

Nats
FNMA
gdog gdog 10 minutes ago
Just bought cyn @.57 and sold .89 + .32 less than 15 minutes wow that was awsome all in pre
Doktornolittle Doktornolittle 10 minutes ago
Scale: Biogen MCap dropped $20B when aducanumab P3 first failed in December of 2019. That $20B had the chance of failure factored in, so if you say 50:50 which would have been extremely optimistic for a P3, the market had valued aducanumab at about $40B for the US prior to P3 results. The EU is a
AVXL
Super hipper Super hipper 11 minutes ago
I think we are going to break .72 resistance before opening. We just need volume.
TNXP
green maschine green maschine 11 minutes ago
Stair-stepping up nicely. 💲1 today is looking GOOD.
TNXP
glenn1919 glenn1919 11 minutes ago
invz........................................https://stockcharts.com/h-sc/ui?s=invz&p=W&b=5&g=0&id=p86431144783
INVZ
DiamondKnight63 DiamondKnight63 12 minutes ago
Thanks for the lesson: Merry Christmas

To pitch or convince or introduce or sell, the investment.

Sale is always a noun. It most commonly refers to the act of or an instance of offering things for purchase, a discounting of such things, or a completed transaction. It’s
ASPZ
gdog gdog 12 minutes ago
I'm posting on Twitter now under Megabuxs
Moonboy1 Moonboy1 12 minutes ago
Wow. Looking great this morning. Back to pre offering price already
TNXP

Your Recent History

Delayed Upgrade Clock